Methods for treating diseases using isoindoline compounds
Methods of treating a disease selected from dermatomyositis, prurigo nodularis, pyoderma gangrenosum, alopecia areata, hidradenitis suppurtiva, rosacea, lichen planus, giant cell arteritis, Sjogren's syndrome, gout, chronic prostatitis, posterior uveitis, vulvodynia and interstitial cystitis in a human are disclosed. Specific methods encompass the administration of (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, cyclopropyl {2-[(15)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindolin-4-yl}carboxamide or a combination thereof, or a pharmaceutically acceptable prodrug, metabolite, polymorph, salt, solvate or clathrate thereof.
1. A method of treating alopecia areata in a human, which comprises administering to a patient having alopecia areata a therapeutically effective amount of a compound which is (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, or a pharmaceutically acceptable salt or solvate thereof, substantially free of its (−)-enantiomer.
2. A method of treating alopecia areata in a human, which comprises administering to a patient having alopecia areata a pharmaceutical composition comprising a therapeutically effective amount of (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, or a pharmaceutically acceptable salt or solvate thereof, substantially free of its (−)-enantiomer.
3. The method of claim 2 , wherein the pharmaceutical composition further comprises one or more excipients, diluents or carriers.
4. The method of claim 1 , wherein the compound is administered as a pharmaceutically acceptable salt.
5. The method of claim 1 , wherein the compound is administered as a pharmaceutically acceptable solvate.
6. The method of claim 5 , wherein the solvate is a hydrate.
7. The method of claim 1 , further comprising administering to the patient a therapeutically effective amount of a second active agent.
8. The method of claim 7 , wherein the second active agent is an anti-inflammatory, an immunomodulatory compound, an anti-malarial, an immunosuppressant, an antibiotic, an antiviral, an immunoglobulin, an immunologic-enhancing drug, a hormone, PGE2 or a combination thereof.
9. The method of claim 8 wherein the second active agent is PGE2.
10. The method of claim 1 , wherein the compound or a pharmaceutically acceptable salt or solvate thereof is administered orally in a dosage form of a tablet or a capsule.
11. The method of claim 10 , wherein the compound or a pharmaceutically acceptable salt or solvate thereof is administered orally in 5 mg, 10 mg, 15 mg, 20 mg, 25 mg or 30 mg of a tablet or a capsule.
12. The method of claim 1 , wherein the therapeutically effective amount is from about 1 mg to about 1000 mg per day.
13. The method of claim 12 , wherein the therapeutically effective amount is from about 5 mg to about 500 mg per day.
14. The method of claim 13 , wherein the therapeutically effective amount is from about 10 mg to about 200 mg per day.
15. The method of claim 1 , wherein the therapeutically effective amount is 20 mg twice per day.
16. The method of claim 1 , wherein the therapeutically effective amount is 30 mg twice per day.
17. The method of claim 1 , wherein the therapeutically effective amount is 40 mg once per day.
18. The method of claim 1 , wherein the compound or a pharmaceutically acceptable salt or solvate thereof is administered once or twice per day.
19. The method of claim 1 , wherein the the compound or a pharmaceutically acceptable salt or solvate thereof is administered cyclically.